Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov24810.25208/0042-4609-2016-92-3-117-122DRUG TREATMENT IN DERMATOVENEROLOGYФАРМАКОТЕРАПИЯ В ДЕРМАТОВЕНЕРОЛОГИИExperience of using tacrolimus as a part of a complex therapy of atopic dermatitisОпыт применения такролимуса в комплексной терапии атопического дерматитаFilimonkovaN. N.ФилимонковаН. Н.
Russian Federation
KascheevaY. V.КащееваЯ. В.
Russian Federation
KolbinaM. S.КолбинаМ. С.
Russian Federation
kolbinamary@mail.ruFGBU “Ural Research Institute of Dermatology and Venereology and immunopathology” Russian Ministry of HealthФГБУ Свердловской области «Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии»Moscow Health Department clinic № 46Городская поликлиника № 46 Департамента здравоохранения города Москвы2406201692311712224082017Copyright ©; 2016, Filimonkova N.N., Kascheeva Y.V., Kolbina M.S.Copyright ©; 2016, Филимонкова Н.Н., Кащеева Я.В., Колбина М.С.2016Filimonkova N.N., Kascheeva Y.V., Kolbina M.S.Филимонкова Н.Н., Кащеева Я.В., Колбина М.С.https://creativecommons.org/licenses/by/4.0https://vestnikdv.ru/jour/article/view/248

This review presents the results of international and Russian clinical studies conducted to assess the efficacy and safety of topical calcineurin inhibitors (TCIs) for the treatment of atopic dermatitis. The main mechanisms of action of TCIs are described. The authors demonstrate the advantages of Tacrolimus belonging to the TCI group. Due to the hydrophilic drug form and pharmacoeconomic index promoting compliance with treatment, it is possible to consider the new drug Tacropic (0.1% and 0.03% Tacrolimus ointments) as the optimum topical drug for the treatment of moderate to severe and severe forms of atopic dermatitis in adults and children.

В обзоре приведены данные зарубежных и отечественных клинических исследований эффективности и безопасности топических ингибиторов кальциневрина (ТИК) в лечении атопического дерматита. Представлены основные механизмы действия ТИК. Показаны преимущества одного из препаратов группы ТИК такролимуса. Гидрофильная лекарственная форма и фармакоэкономический показатель, повышающие комплаентность лечения, позволяют рассматривать новый препарат Такропик (0,1% и 0,03% мазь такролимуса) как оптимальное топическое средство для лечения среднетяжелых и тяжелых форм атопического дерматита у взрослых и детей.

топические ингибиторы кальциневринатакролимусатопический дерматиттопическая терапияклинические исследованияТакропикtopical calcineurin inhibitorsTacrolimusatopic dermatitistopical treatmentclinical studiesTacropicПрошутинская Д.В., Чикин В.В., Знаменская Л.Ф., Монахов К.Н., Заславский Д.В., Минеева А.А. Федеральные клинические рекомендации по ведению больных атопическим дерматитом. Российское общество дерматовенерологов и косметологов. М, 2015; 40.Kino T., Hatanaka H., Hashimoto M. et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987; 40 (9): 1249-55.Stucker F., Ackermann D. [Immunosuppressive drugs - how they work, their side effects and interactions]. Ther Umsch 2011; 68 (12): 679-86.Кочергин Н.Г., Черникова Е.А., Билалова У.Г. Атопический дерматит открытых участков и малассезиозная инфекция. Рос журн кож вен бол 2011; 2: 31-3Ruzichka T., Assmann T., Homey B. Tacrolimus: the drug for the turn of the millennium? Arch. Dermatol 1999; 135 (5): 574-80.Lawrence I.D. Tacrolimus (FK506): experience in dermatology. Dermatol Thier 1998; 5: 74-84.Michel G., Kemeny L., Homey B., Ruzicka T. FK506 in the treatment of inflammatory skin disease: promises and perspectives. Immunol. Today 1996; 17 (3): 106-8.Gupta A.K., Adamiak A., Chow M. Tacrolimus: a review of its use for management of dermatoses. J Eur Acad Dermatol Venereol 2002; 16 (2): 100-14.Fleisher A.B.Jr. Treatment of atopic dermatitis: Role of tacrolimus ointment as a topical non-corticosteroid therapy. J Allergy Clin Immunol 1999; 104 (3, Pt 2): S126-30.Martin Ezquerra G., Sanchez Regana M., Herrera Acosta E., Umbert Millet P.M. Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques. J Drugs Dermatol 2006; 5 (4): 334-6.Hanifin J.M., Paller A.S., Eichenfield L., Clark R.A., Korman N., Weinstein G. et al. US Tacrolimus Ointment Study Group. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol 2005; 53 (2, Suppl. 2): S186-94.Аллергические дерматозы. Ясный взгляд на проблему. VII Международный форум дерматовенерологов и косметологов «Эффективная фармакотерапия». Дерматовенер дерматокосметол 2014; 3-4 (48)Nakagawa H. Comparison of the efficacy and safety of 0.1% tacrolimus ointment with topical corticosteroids in adult patients with atopic dermatitis: review of randomized, double_blind clinical studies conducted in Japan. Clin Drug Invest 2006; 26: 235-246.Paller A.S., Eichenfield L.F., Leung D.Y.M. et al. A 12 week study of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol 2001; 44: S47-57.Reitamo S., Harper J., Bos J. et al. Therapeutics 0.03% tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double_blind controlled trial. Br J Dermatol 2004; 150: 554-562.Reitamo S., Ortonne J.P., Sand C. et al. Long_term treatment with 0.1% tacrolimus ointment in adults with atopic dermatitis: results of a two_year, multicentre, non_com-parative study. Acta Derm Venereol 2007; 87: 406-412.Hanifin J.M., Ling M.R., Langley R., Breneman D., Rafal E.Tacrolimus ointment for the treatment of atopic dermatitis in adults patients: Part I, efficacy. J Am Acad Dermatol 2001; 44: 28-38.Paller A.S., Eichenfield L.F., Leung D.Y.M. et al. A 12 week study of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol 2001; 44: S47-57.Kempers S., Boguniewicz M., Carter E. et al. A randomized inverstigator_blinded study comparing pimecrolimus cream 1% with tacrolimus 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 2004; 51: 515-525.Fukushima H., Hirano T., Shibayama N. et al. The role of immune response to Staphylococcus aureus superantigens and disease severity in relation to the sensitivity to tacrolimus in atopic dermatitis. Int Arch Allergy Immunol 2006; 141: 281-289.Nakagawa H., Etoh T., Yokota Y. et al. Tacrolimus has antifungal activities against Malassezia furfur isolated from healthy adults and patients with atopic dermatitis. Clin Drug Invest 1996; 12: 244-250.Antiga E., Volpi W., Torchia D. et al. Effects of tacrolimus ointment on Toll_like receptors in atopic dermatitis. Clin Exp Dermatol 2010; 36: 235-241.Bieber T., Cork M., Ellis C. et al. Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology 2005; 211: 77-78.Fonacier L., Spergel J., Ernest N. et al. Report of the topical calcineurin inhibitor task force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2005; 115: 1249-1253.Sidbury R., Davis D.M., Cohen D.E., Cordoro K.M., Berger T.G., Bergman J.N., Chamlin S.L., Cooper K.D., Feldman S.R., Hanifin J.M., Krol A., Margolis D.J., Paller A.S., Schwarzenberger K., Silverman R.A., Simpson E.L., Tom W.L., Williams H.C., Elmets C.A., Block J., Harrod C.G., Begolka W.S., Eichenfield L.F.; American Academy of Dermatology. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 2014; 71 (2): 327-49.Nakahara T., Koga T., Fukagawa S., Uchi H., Furue M. Intermittent topical corticosteroid/tacrolimus sequential therapy improves lichenification and chronic papules more efficiently than intermittent topical corticosteroid/emollient sequential therapy in patients with atopic dermatitis. J Dermatol 2004; 31: 524-8.Hebert A.A., Koo J., Fowler J., Berman B., Rosenberg C., Levitt J. Desoximetasone 0.25% and tacrolimus 0.1% ointments versus tacrolimus alone in the treatment of atopic dermatitis. Cutis 2006; 78: 357-63.Torok H.M., Maas-Irslinger R., Slayton R.M. Clocortolone pivalate cream 0.1% used concomitantly with tacrolimus ointment 0.1% in atopic dermatitis. Cutis 2003; 72: 161-6.Spergel J.M., Boguniewicz M., Paller A.S., Hebert A.A., Gallagher P.R., McCormick C., Parneix-Spake A., Hultsch T. Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial. Br J Dermatol 2007; 157 (2): 378-81.Thaçi D., Reitamo S., Gonzalez Ensenat M.A., Moss C., Boccaletti V., Cainelli T., van der Valk P., Buckova H., Sebastian M., Schuttelaar M.L., Ruzicka T.; European Tacrolimus Ointment Study Group. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol. 2008; 159 (6): 1348-56.Paller A.S., Eichenfield L.F., Kirsner R.S., Shull T., Jaracz E., Simpson E.L.; US. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis:a new paradigm for use; Pediatrics, 2008; 122 (6): e1210-8.Crissinger A., Nguyen N. The Use of Topical Calcineurin Inhibitors in Atopic Dermatitis. The Open Dermatology Journal 2014; 8: 12-17.Бакулев А.Л. Такролимус: 10 лет успешного применения в клинической практике. Вестн дерматол венерол 2010; 6: 23-37